Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

HTA reports published by Spanish Carlos III Health Institute in October 2026

In October 2026, the Carlos III Health Institute (ISCIII), working under the Spanish Network of HTA Agencies (RedETS), released four health technology assessments.

One example is an assessment of percutaneous repair and replacement systems for treating tricuspid valve insufficiency. Key conclusions included the following:

  • For repair procedures, edge-to-edge systems (TriClip, PASCAL) are considered the most mature technologies. Evidence for annuloplasty and spacer devices are based on single-arm studies;
  • For replacement procedures, orthotopic replacement with EVOQUE has the strongest evidence;
  • Of the 59 prospective studies identified, only four were RCTs, and most were small single-arm studies with short follow-up and no comparator. Several devices remain at the early feasibility stage without CE marking or FDA approval;
  • No cost-effectiveness studies were identified; 
  • Implementation would not require major organizational changes, as procedures can use TAVI settings. However, it would require transesophageal echocardiography capacity, clearly defined indications for patient access, and structured team training.

Two other published reports relate to in-vitro diagnostics, and another one concern digital therapeutic technology for panic disorder and post-traumatic stress disorder. 

This news is just one of about 300 market access news and updates collected by our team in the premium subscription service MTRC Access Intelligence every week from more than 80 organizations. Access our paid service to stay on top of all developments, specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, six-week, no-obligation trial.